estin by Upjohn Generic Manufacturers Major Qualitest Rosemont Rugby URL Pharmacology Apparently similar to endogenous testosterone Delivery 2, 5, 10mg oral tablets Typical dosage Pre-op ? Post-op 5-20mg/day Availability Approved by U.S. FDA. Schedule III controlled substance. Indications Breast cancer in females. Hormone replacement therapy in males. Contraindications Hypersensitivity to any component of the product. Heart, liver, and kidney disease. Known breast cancer. Adverse reactions CNS Anxiety. Depression. Headache. Prickling or tingling skin. Eyes Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Oily skin. Other Mild to extreme allergic reaction. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors. Risk FactorsIt is now certain that androgen treatment has an unfavorable effect on the lipid profile. It places female-to-male transsexuals in the risk category of men; therefore, patients must be advised not to smoke, to exercise moderately, and to prevent extreme weight gain and high blood pressure. After surgical sex reassignment including ovariectomy, androgen therapy must be continued to prevent symptoms of hormone deprivation and osteoporosis. Discontinuation of cross-sex hormones following surgical adaptation to the desired sex leads to loss of bone mineral density. It is necessary to temporarily discontinue sex steroid administration 3-4 weeks before any elective surgical intervention. Immobilization is a trombogenic risk factor and sex steroids may aggravate the risk of thromboembolism. Once subjects are fully mobilized again, hormone therapy may be reinstated. ...
